- Home
- AFCG vs VNRX Comparison
AFCG vs VNRX Comparison
Compare AFCG & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFCG
- VNRX
- Stock Information
- Founded
- AFCG 2020
- VNRX N/A
- Country
- AFCG United States
- VNRX United States
- Employees
- AFCG N/A
- VNRX N/A
- Industry
- AFCG Real Estate Investment Trusts
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- AFCG Real Estate
- VNRX Health Care
- Exchange
- AFCG Nasdaq
- VNRX Nasdaq
- Market Cap
- AFCG 71.9M
- VNRX 69.7M
- IPO Year
- AFCG 2021
- VNRX N/A
- Fundamental
- Price
- AFCG $3.13
- VNRX $0.33
- Analyst Decision
- AFCG Hold
- VNRX Strong Buy
- Analyst Count
- AFCG 4
- VNRX 4
- Target Price
- AFCG $5.75
- VNRX $3.50
- AVG Volume (30 Days)
- AFCG 145.7K
- VNRX 895.9K
- Earning Date
- AFCG 11-12-2025
- VNRX 11-13-2025
- Dividend Yield
- AFCG 19.17%
- VNRX N/A
- EPS Growth
- AFCG N/A
- VNRX N/A
- EPS
- AFCG N/A
- VNRX N/A
- Revenue
- AFCG N/A
- VNRX $1,319,252.00
- Revenue This Year
- AFCG N/A
- VNRX $324.32
- Revenue Next Year
- AFCG $13.92
- VNRX $247.82
- P/E Ratio
- AFCG N/A
- VNRX N/A
- Revenue Growth
- AFCG N/A
- VNRX 35.10
- 52 Week Low
- AFCG $3.04
- VNRX $0.33
- 52 Week High
- AFCG $9.93
- VNRX $0.94
- Technical
- Relative Strength Index (RSI)
- AFCG 35.93
- VNRX 21.92
- Support Level
- AFCG $3.04
- VNRX $0.37
- Resistance Level
- AFCG $3.35
- VNRX $0.41
- Average True Range (ATR)
- AFCG 0.15
- VNRX 0.04
- MACD
- AFCG 0.02
- VNRX -0.00
- Stochastic Oscillator
- AFCG 21.08
- VNRX 1.59
About AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to cannabis operators in the U.S. Through the management team's deep network and related credit and cannabis expertise. The company originates, structures, and underwrites loans secured by quality real estate assets, license value, and cash flows.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.